ESH MDS 2024 | The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus, PhD, University Hospital Carl Gustav Carus, Dresden, Germany, briefly outlines the role of the bone marrow microenvironment in hematological malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The bone marrow microenvironment presents an important target for novel therapies, and a focus should be placed not only on eradicating leukemic cells but also on restoring normal hematopoiesis following eradication. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
The bone marrow microenvironment supports normal hematopoiesis, but also plays a major role in the expansion of the leukemic cells in a malignancy, or either in a premalignant state, but later on also when the MDS progresses to acute myeloid leukemia. The leukemic cells mimic and manipulate the stromal microenvironment to their advantage, and this is all accompanied or with an inhibition of the normal hematopoiesis and, therefore, the bone marrow microenvironment has also targets for therapies and is manipulated and modulated by any therapeutical approach...
The bone marrow microenvironment supports normal hematopoiesis, but also plays a major role in the expansion of the leukemic cells in a malignancy, or either in a premalignant state, but later on also when the MDS progresses to acute myeloid leukemia. The leukemic cells mimic and manipulate the stromal microenvironment to their advantage, and this is all accompanied or with an inhibition of the normal hematopoiesis and, therefore, the bone marrow microenvironment has also targets for therapies and is manipulated and modulated by any therapeutical approach. And this needs always to be taken into consideration, both for the treatment of the disease, but also after eradication of the leukemic cells also to improve again the normal hematopoiesis.
Read more...
Disclosures
Research Funding: Active Biotech.
